What are the indications, dosing regimen, and safety considerations for lumefantrine (artemether‑lumefantrine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Artemether-Lumefantrine (Coartem)

Artemether-lumefantrine is a first-line artemisinin-based combination therapy for treating uncomplicated Plasmodium falciparum malaria in patients weighing ≥5 kg, with recent evidence supporting an extended 5-day (10-dose) regimen for travelers to improve cure rates. 1, 2

Indications

Artemether-lumefantrine is indicated for:

  • Uncomplicated P. falciparum malaria in patients ≥5 kg body weight 3
  • Effective in regions with chloroquine resistance 3
  • Not for severe malaria or malaria prophylaxis 3

The drug combines artemether (fast-acting, short half-life) with lumefantrine (slower-acting partner drug) to provide rapid parasite clearance and prevent recrudescence 1.

Dosing Regimen

Standard 3-Day (6-Dose) Regimen

Weight-based dosing (each tablet contains artemether 20 mg + lumefantrine 120 mg) 1, 3:

  • 5 to <15 kg: 1 tablet per dose
  • 15 to <25 kg: 2 tablets per dose
  • 25 to <35 kg: 3 tablets per dose
  • ≥35 kg (adults): 4 tablets per dose

Timing: Initial dose at H0, second dose at H8, then twice daily (morning and evening) at H24, H36, H48, H60, and H72 for total of 24 tablets over 72 hours in adults 1

Updated Extended 5-Day (10-Dose) Regimen

Recent CDC guidance (2025) now recommends a 5-day (10-dose) course for treating uncomplicated P. falciparum malaria in the United States due to increasing treatment failures with the standard regimen, particularly among travelers from Africa 2. This extended regimen:

  • Achieves higher lumefantrine exposure
  • Addresses late recrudescences occurring 1-8 weeks post-treatment
  • Is well tolerated with no significant safety concerns 2

Critical Administration Requirements

Must be taken with fatty food or drink to optimize lumefantrine absorption 1, 3. This is essential for efficacy. Tablets may be crushed and mixed with 1-2 teaspoons of water for children 3.

Safety Considerations

Contraindications

  • Known hypersensitivity to artemether, lumefantrine, or excipients 3
  • Coadministration with strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) 3

Warnings and Precautions

QT Prolongation Risk 1, 3:

  • Avoid in patients with known QT prolongation
  • Avoid in those with hypokalemia or hypomagnesemia
  • Use caution with other QT-prolonging drugs
  • Halofantrine must not be given within 1 month of artemether-lumefantrine due to additive QT effects
  • Quinine and quinidine should be used cautiously following treatment

Drug Interactions 3, 4:

  • CYP3A4 inhibitors: May increase QT prolongation risk
  • Antiretrovirals: Use cautiously—efavirenz reduces lumefantrine exposure by 17% 4; potential for loss of antiviral or antimalarial efficacy
  • Hormonal contraceptives: Effectiveness may be reduced; use additional contraception 3
  • Mefloquine: If used immediately before treatment, monitor for decreased efficacy and encourage food intake 3

Pregnancy

Artemether-lumefantrine can be used in all trimesters of pregnancy per WHO and CDC guidelines 1. Updated 2018 CDC recommendations state [5-5]:

  • Preferred for 2nd and 3rd trimesters with strong safety evidence
  • Can be used in 1st trimester when other options unavailable (mefloquine or quinine plus clindamycin preferred if available)
  • Systematic reviews show no increased risk of miscarriage, stillbirth, preterm birth, low birth weight, or congenital abnormalities compared to other antimalarials

Common Adverse Reactions

Adults (>30%): Headache, anorexia, dizziness, asthenia, arthralgia, myalgia 3

Children (>12%): Pyrexia, cough, vomiting, anorexia, headache 3

Most adverse events are mild-to-moderate and often attributable to malaria itself 6, 7. Serious adverse events occur in approximately 1.3-1.4% of patients 6.

Efficacy

High cure rates demonstrated 6, 7:

  • 28-day PCR-corrected cure rate: 97.1% in adults, 97.3% in children 6
  • Rapid parasite clearance (median 41.5 hours) and fever clearance (median 36.8 hours) 7
  • Gametocytemia prevalence after day 7: 4.2% in adults, 0.9% in children 6

Emerging concern: Treatment failure rates among travelers have increased, particularly for infections acquired in Africa, with 7% failure risk in data from 2018 or later versus 4% before 2018 2. This prompted the updated CDC recommendation for extended 5-day dosing.

Clinical Pitfalls

  1. Food requirement: Failure to take with fatty food significantly reduces lumefantrine absorption and treatment efficacy 1, 8
  2. Pregnancy-related anorexia and food taboos may compromise absorption in pregnant women 8
  3. Geographic resistance patterns: Established resistance in Greater Mekong sub-region; emerging concerns in Africa 1, 2
  4. Late recrudescences: 85% of treatment failures occur 1-8 weeks post-treatment, often presenting as severe malaria 2
  5. Complex dosing schedule: The 6-dose regimen over 3 days requires careful patient counseling for adherence 1

References

1
Guideline

how to manage adult patients with malaria in the non-endemic setting.

Clinical Microbiology and Infection, 2024

Related Questions

How should artemether/lumefantrine be dosed for uncomplicated Plasmodium falciparum malaria in adults and children, and what are the guidelines for severe cases?
Can a mother receiving the standard artemether/lumefantrine (Riamet) regimen (20 mg + 120 mg per tablet, four tablets twice daily for three days) breastfeed?
Has the CDC changed its recommendation for artemether‑lumefantrine 80 mg/480 mg dosing in uncomplicated Plasmodium falciparum malaria to twice daily for five days instead of the standard three‑day regimen?
Can artemether‑lumefantrine (Coartem) be used to treat uncomplicated Plasmodium falciparum malaria in a pregnant woman, and what are the recommended trimester‑specific safety considerations and dosing regimen?
What is the recommended dosage, administration schedule, and required fatty intake for oral artemether‑lumefantrine when transitioning from intravenous artesunate in a patient with Plasmodium falciparum malaria, and what clinical signs of stability, fever and rigors trends, and timing indicate when to switch to artemether‑lumefantrine therapy?
What are the causes of calcified mediastinal lymph nodes?
When are fosfomycin and trimethoprim‑sulfamethoxazole appropriate treatments for uncomplicated cystitis?
Does fosfomycin contain a sulfonamide (sulfa) component?
How should a patient with an INR of 7.79 and no bleeding be managed?
What is the FDA pregnancy safety category for trazodone?
What is the appropriate management of hyperkalemia and bowel ileus in a one‑month‑old infant?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.